Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 45 2024-01-01 false No description of principal activity 32 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07417662 2024-01-01 2024-12-31 07417662 2023-01-01 2023-12-31 07417662 2024-12-31 07417662 2023-12-31 07417662 2023-01-01 07417662 c:Director2 2024-01-01 2024-12-31 07417662 d:CurrentFinancialInstruments 2024-12-31 07417662 d:CurrentFinancialInstruments 2023-12-31 07417662 d:Non-currentFinancialInstruments 2024-12-31 07417662 d:Non-currentFinancialInstruments 2023-12-31 07417662 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 07417662 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 07417662 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 07417662 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 07417662 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-12-31 07417662 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-12-31 07417662 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-12-31 07417662 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-12-31 07417662 d:ShareCapital 2024-01-01 2024-12-31 07417662 d:ShareCapital 2024-12-31 07417662 d:ShareCapital 2023-01-01 2023-12-31 07417662 d:ShareCapital 2023-12-31 07417662 d:ShareCapital 2023-01-01 07417662 d:SharePremium 2024-01-01 2024-12-31 07417662 d:SharePremium 2024-12-31 07417662 d:SharePremium 2023-01-01 2023-12-31 07417662 d:SharePremium 2023-12-31 07417662 d:SharePremium 2023-01-01 07417662 d:CapitalRedemptionReserve 2024-01-01 2024-12-31 07417662 d:CapitalRedemptionReserve 2024-12-31 07417662 d:CapitalRedemptionReserve 2023-01-01 2023-12-31 07417662 d:CapitalRedemptionReserve 2023-12-31 07417662 d:CapitalRedemptionReserve 2023-01-01 07417662 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 07417662 d:RetainedEarningsAccumulatedLosses 2024-12-31 07417662 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 07417662 d:RetainedEarningsAccumulatedLosses 2023-12-31 07417662 d:RetainedEarningsAccumulatedLosses 2023-01-01 07417662 c:FRS102 2024-01-01 2024-12-31 07417662 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 07417662 c:FullAccounts 2024-01-01 2024-12-31 07417662 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07417662 d:Subsidiary1 2024-01-01 2024-12-31 07417662 d:Subsidiary1 1 2024-01-01 2024-12-31 07417662 2 2024-01-01 2024-12-31 07417662 6 2024-01-01 2024-12-31 07417662 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 07417662 P1VITAL PRODUCTS LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2024
P1VITAL PRODUCTS LIMITED REGISTERED NUMBER: 07417662 BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Investments |  |  | 5,891 |  | -
|  |  | 5,891 |  | -
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 6 | 1,197,483 |  | 1,091,989 |
Cash at bank and in hand | 7 | 185,245 |  | 76,898 |
|  | 1,382,728 |  | 1,168,887 |
Creditors: amounts falling due within one year | 8 | (1,195,923) |  | (853,748) |
Net current assets |  |  | 186,805 |  | 315,139
Total assets less current liabilities |  |  | 192,696 |  | 315,139
Creditors: amounts falling due after more than one year | 9 |  | (21,667) |  | (19,167)
Net assets |  |  | 171,029 |  | 295,972
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 77 |  | 76
Share premium account |  |  | 2,160 |  | 2,160
Capital redemption reserve |  |  | 52 |  | 52
Profit and loss account |  |  | 168,740 |  | 293,684
|  |  | 171,029 |  | 295,972
Page 1
P1VITAL PRODUCTS LIMITED REGISTERED NUMBER: 07417662 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................ J A Kingslake
Director
Date: 9 September 2025
The notes on pages 5 to 14 form part of these financial statements. Page 2
P1VITAL PRODUCTS LIMITED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2024
| Called up share capital | Share premium account | Capital redemption reserve | Profit and loss account | Total equity
| £ | £ | £ | £ | £
At 1 January 2024 | 76 | 2,160 | 52 | 293,684 | 295,972
Comprehensive income for the year |  |  |  |  |
Loss for the year | - | - | - | (124,944) | (124,944)
Other comprehensive income for the year | - | - | - | - | -
Total comprehensive income for the year | - | - | - | (124,944) | (124,944)
Contributions by and distributions to owners |  |  |  |  |
Shares issued during the year | 1 | - | - | - | 1
Total transactions with owners | 1 | - | - | - | 1
At 31 December 2024 | 77 | 2,160 | 52 | 168,740 | 171,029
| The notes on pages 5 to 14 form part of these financial statements.
Page 3
P1VITAL PRODUCTS LIMITED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2023
| Called up share capital | Share premium account | Capital redemption reserve | Profit and loss account | Total equity
| £ | £ | £ | £ | £
At 1 January 2023 | 126 | 2,160 | 2 | 590,085 | 592,373
Comprehensive income for the year |  |  |  |  |
Profit for the year | - | - | - | 120,599 | 120,599
Other comprehensive income for the year | - | - | - | - | -
Total comprehensive income for the year | - | - | - | 120,599 | 120,599
Contributions by and distributions to owners |  |  |  |  |
Purchase of own shares | - | - | 50 | (417,000) | (416,950)
Shares issued during the year | (50) | - | - | - | (50)
Total transactions with owners | (50) | - | 50 | (417,000) | (417,000)
At 31 December 2023 | 76 | 2,160 | 52 | 293,684 | 295,972
| The notes on pages 5 to 14 form part of these financial statements.
Page 4
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
1. | General information
P1vital Products Limited is a private limited company incorporated in England & Wales. The registered office is Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA. The principal activity of the company is that of a research and experimental development in natural sciences. The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Page 5
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.3 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.4 | Research and development
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years. If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
| 2.5 | Interest income
Interest income is recognised in profit or loss using the effective interest method. Page 6
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.6 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.7 | Share-based payments
Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition. The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Company keeping the scheme open or the employee maintaining any contributions required by the scheme). Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period. Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received. Page 7
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.8 | Current and deferred taxation
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
| 2.9 | Valuation of investments
Investments in subsidiaries are measured at cost less accumulated impairment.
| 2.10 | Debtors
Short term debtors are measured at transaction price, less any impairment.
| 2.11 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.12 | Long-term contracts
Profit on long-term contracts is taken as the work is carried out if the final outcome can be assessed with reasonable certainty. The profit included is calculated on a prudent basis to reflect the proportion of the work carried out at the year end, by recording turnover relates costs as contract activity progresses. Turnover is calculated as that proportion of total contract value for which costs iincurred to date bear to total expected costs for that contract. Full provision is made for losses on all contracts in the year in which they are first foreseen.
| 2.13 | Creditors
Short term creditors are measured at the transaction price. Page 8
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.14 | Government grants
Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income. Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.
| 2.15 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.16 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.
| 2.17 | Borrowing costs
All borrowing costs are recognised in profit or loss in the year in which they are incurred.
3. | Judgments in applying accounting policies and key sources of estimation uncertainty
In applying the company’s accounting policies, the directors are required to make judgements, estimated and assumptions regarding the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on management’s best knowledge of the amount, event or actions, actual results may differ from those estimates. Page 9
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
4. | Employees
| The average monthly number of employees, including directors, during the year was 32 (2023 - 45).
5. | Fixed asset investments
|  | Investments in subsidiary companies
|  | £
| Cost or valuation |
| Additions | 5,891
| At 31 December 2024 | 5,891
| Subsidiary undertaking
| The following was a subsidiary undertaking of the Company:
| Name | Registered office | Class of shares | Holding
| P1vital Limited | Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA | Ordinary | 100%
| On 5 December 2024, the company acquired 100% of the share capital and trade and assets of P1vital Limited, a company incorporated in the United Kingdom.
6. | Debtors
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade debtors | 421,210 | 353,914
| Amounts owed by related parties | 29,718 | 33,989
| Other debtors | 16,151 | 32,079
| Called up share capital not paid | 103 | 103
| Prepayments and accrued income | 48,470 | 79,032
| Amounts recoverable on long term contracts | 353,248 | 315,556
| Tax recoverable | 328,583 | 277,316
|  | 1,197,483 | 1,091,989
Page 10
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
7. | Cash and cash equivalents
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Cash at bank and in hand | 185,245 | 76,898
|  | 185,245 | 76,898
8. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank loans | 20,000 | 10,000
| Trade creditors | 186,734 | 196,392
| Other taxation and social security | 42,028 | 51,798
| Other creditors | 542,752 | 275,877
| Accruals and deferred income | 404,409 | 319,681
|  | 1,195,923 | 853,748
9. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank loans | 21,667 | 19,167
|  | 21,667 | 19,167
Page 11
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
10. | Loans
| Analysis of the maturity of loans is given below:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Amounts falling due within one year |  |
| Bank loans | 20,000 | 10,000
|  | 20,000 | 10,000
| Amounts falling due 1-2 years |  |
| Bank loans | 19,167 | 10,000
|  | 19,167 | 10,000
| Amounts falling due 2-5 years |  |
| Bank loans | 2,500 | 9,167
|  | 2,500 | 9,167
|  | 41,667 | 29,167
Page 12
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
11. | Share-based payments
| The company operates an Enterprise Management Incentive scheme. Share options are issues under the terms of a 3 year vesting period and require that the holder remains employed by the company throughout. During the year, 2,000 Ordinary B Shares lapsed. At the year end options of 12,000 Ordinary B Shares to 2 employees remain in issue. The options become exercisable at various dates up to 10 years from grant and all have an exercise price of 3p per share.
|  | Weighted average exercise price (pence) 2024 | Number 2024 | Weighted average exercise price (pence) 2023 | Number 2023
| Outstanding at the beginning of the year | 3 | 14,000 | 3 | 14,000
| Expired during the year |  | (2,000) |  | -
| Outstanding at the end of the year | 3 | 12,000 | 3 | 14,000
12. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £42,224 (2023 - £46,598).
13. | Related party transactions
| During the year the company made sales and purchases at an arm's length basis to a company with common control and key management personnel. The aggregate transactions during the year and the balance outstanding as at the year end is set out below:
|  | 2024 | 2023
|  | £ | £
| Balance outstanding due to related parties | - | -
| Balance outstanding due from related parties | 29,718 | 33,989
Page 13
P1VITAL PRODUCTS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
14. | Controlling party
During the reporting period, the company completed a merger with P1vital Limited and restructuring of its business. P1vital Products Limited is controlled by J A Kingslake and Dr G R Dawson, who are considered the company’s ultimate beneficial owners.
Page 14